Editor's Note
The Food and Drug Administration (FDA) on May 8 sent a letter to healthcare providers that included recommendations on the use of neurovascular stents for stent-assisted coiling in the treatment of unruptured brain aneurysms.
The FDA has received reports associated with these devices that suggest events of peri-procedural stroke and/or death may have been related to procedural risks or patient selection factors. These include patients with serious comorbidities resulting in a reduced life expectancy or who were intolerant to anticoagulation or antiplatelet therapy.
The promise of quicker recovery and fewer complications from sedation,…
New York, New York (January 31, 2024)–Sonio today announced that…
The US Food and Drug Administration receives more than 100,000…